Potential utility of melatonin as an antioxidant during pregnancy and in the perinatal period

Salvatore Aversa, Salvatore Pellegrino, Ignazio Barberi, Russel J. Reiter, Eloisa Gitto

Research output: Contribution to journalReview article

44 Scopus citations

Abstract

Reactive oxygen species (ROS) play a critical role in the pathogenesis of various diseases during pregnancy and the perinatal period. Newborns are more prone to oxidative stress than individuals later in life. During pregnancy, increased oxygen demand augments the rate of production of ROS and women, even during normal pregnancies, experience elevated oxidative stress compared with non-pregnant women. ROS generation is also increased in the placenta during preeclampsia. Melatonin is a highly effective direct free-radical scavenger, indirect antioxidant, and cytoprotective agent in human pregnancy and it appears to be essential for successful pregnancy. This suggests a role for melatonin in human reproduction and in neonatal pathologies (asphyxia, respiratory distress syndrome, sepsis, etc.). This review summarizes current knowledge concerning the role for melatonin in human pregnancy and in the newborn. Numerous studies agree that short-term melatonin therapy is highly effective in reducing complications during pregnancy and in the neonatal period. No significant toxicity or treatment-related side effects with long-term melatonin therapy in children and adults have been reported. Treatment with melatonin might result in a wide range of health benefits, including improved quality of life and reduced healthcare costs.

Original languageEnglish (US)
Pages (from-to)207-221
Number of pages15
JournalJournal of Maternal-Fetal and Neonatal Medicine
Volume25
Issue number3
DOIs
Publication statusPublished - Mar 1 2012

    Fingerprint

Keywords

  • Melatonin
  • free radicals
  • human
  • newborn
  • oxidative stress
  • preeclampsia
  • pregnancy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology

Cite this